Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics

/Home/Diabetes Treatment/Clinical Trial Resources for Diabetes/Diabetes Clinical Trials - Completed

Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics

This study has been completed.
Sponsors and Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network

Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00057499

Purpose
Insulin dependent diabetes mellitus (also called type 1 diabetes mellitus or T1DM) is caused by the destruction of insulin-producing cells in the pancreas. People with T1DM do not produce enough insulin, which is necessary for proper regulation of blood sugar levels.

T1DM is an autoimmune disease. An autoimmune disease is a disease in which the body's immune system attacks the body itself. In addition to regulating blood sugar, insulin may have the ability to protect cells in the pancreas from attack by the immune system. This study will evaluate whether an insulin-based vaccine can protect cells from autoimmune destruction.

Study hypothesis: IFA-enhanced human insulin B-chain vaccination will lead to the arrest or slowing of the ongoing autoimmunity, and this will result in an appreciable difference in functioning B cell mass compared to the placebo treated group by the end of the study.

Condition Intervention Phase
Insulin-Dependent Diabetes Mellitus
Diabetes Mellitus
Biological: IBC-VS01
Biological: IBC-VS01 placebo
Phase I

MedlinePlus related topics: Autoimmune Diseases Diabetes Diabetes Type 1
Drug Information available for: Insulin
U.S. FDA Resources
Study Type:Interventional
Study Design:Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety Study
Official Title:Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
Clinical endpoints including adverse events, local reactions, routine physical exams, insulin dose, and laboratory tests [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
C-peptide levels in response to mixed meal tolerance test [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

HbA1c, GAD65Ab, IAA, IA2Ab, GAD65Ab isotypes [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

CD4- and CD8- Va24JaQ+ [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

T cells' secretion of IL-4 and INF-gamma [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Enrollment:12
Study Start Date:March 2003
Study Completion Date:March 2007

Arms Assigned Interventions
1: Experimental
IBC-VS01 vaccine administered twice Biological: IBC-VS01
IBC-VS01
2: Placebo Comparator
IBC-VS01 placebo administered twice Biological: IBC-VS01 placebo
IBC-VS01 placebo

Detailed Description:
The vaccine in this study, IBC-VSO1, is a synthetic, metabolically inactive form of insulin designed to prevent pancreatic beta-cell destruction. It does not cause fluctuations in blood sugar. This study will evaluate whether the vaccine protects against autoimmune attack at the onset of T1DM, before pancreas function has deteriorated. This experimental treatment must occur early because 60% to 85% of beta-cells are already destroyed by the time of T1DM diagnosis. If beta-cell destruction can be halted, a prolonged remission period after diagnosis may occur, with a subsequent delay in diabetes-related complications.

Participants must have been diagnosed with T1DM for no more than 3 months at the time of enrollment in this study. Participants will be randomly assigned to either a vaccine group or a control group. Participants in the vaccine group will receive one injection of IBC-VS01; participants in the control group will receive a placebo. Participants will then be monitored for 2 years. Participants will have ten follow-up visits, which will include blood tests for immunological and genetic analysis. Throughout the study, metabolic tests will also be performed to measure the remaining capacity of self insulin production of the body.

Eligibility
Ages Eligible for Study:18 Years to 35 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria
Inclusion Criteria:

Diagnosed with type 1 diabetes mellitus within 3 months prior to study entry
Positive for IAA, GAD65, or IA2 antibodies OR positive for GAD65 or IA2 antibodies after 2 weeks of starting insulin treatment
Exclusion Criteria:

History of treatment with any oral hypoglycemic agent for more than 3 months
Ongoing use of medications known to influence glucose tolerance
History of immunosuppressive or steroid therapy for more than 3 months within the 2 years prior to study entry
Severe active liver, heart, kidney, or immunodeficiency disease that may limit life expectancy or may require immunosuppression during the study
Prior complications related to routine vaccinations
Prior participation in a trial for prevention of type 1 diabetes mellitus. Individuals who are known to have been in the placebo arm of a completed prevention trial are not excluded.
Any condition that may interfere with a participant's ability to comply with the study
Pregnancy or planned pregnancy within the time frame of the study
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00057499

Locations
United States, Massachusetts
Children's Hospital
Boston, Massachusetts, United States, 02115
Joslin Diabetes Center
Boston, Massachusetts, United States, 02215

Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network
Investigators
Principal Investigator: Tihamer Orban, MD Joslin Diabetes Center

Click here for the Immune Tolerance Network Web site

Study ID Numbers:ITN012AI, DAIT BD012
First Received:April 3, 2003
Last Updated:September 29, 2008
ClinicalTrials.gov Identifier:NCT00057499 [history]
Health Authority:United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Juvenile diabetes
Diabetes
Insulin
Vaccine
Type 1 Diabetes
Diabetes Mellitus

Study placed in the following topic categories:
Autoimmune Diseases
Metabolic Diseases
Diabetes Mellitus, Type 1
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:
Immune System Diseases